Lenskart, the first of its kind online optical store in India, has made it possible to acquire a good quality pair of specs with prescription lenses for just Rs. 399. With a 48-hour free home delivery guarantee and 365 days return policy, Lenskart.com is doing what e-commerce hasn’t been able to do in India yet. The website has over 500 designs of eye frames, in multiple colors, for all age groups, from Rs. 399 all the way to Rs. 4,000 for a pair. All one needs to do is select a frame, fill in their power, and place an order. You can pay online or at the time of delivery. Lenskart.com has the biggest collection of discounted contact lenses consisting of all top-notch brands (viz. Johnson & Johnson, Bausch & Lomb, Ciba Vision to name a few) and be it disposable, toric, colored, or bifocal contact lenses, you can find all possible types here. Lenskart is dedicated to providing its customers with a simple, hassle-free way to replace their contact lenses. One can receive the exact same contact lens, their doctor prescribed, delivered to their door, at a great price.
ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
HAYA Therapeutics is a developer of RNA-based therapeutics created to treat heart failure. The company's therapeutics utilizes biopharmaceutical therapy to target a heart specific regulator of fibrosis, the long noncoding RNA, enabling physicians to to block myocardial fibrosis and treat heart failure.
Bizongo develops a tech-enabled B2B e-commerce and supply chain platform for packaging, apparel, and other customized goods. It digitally transforms the fragmented and unorganized yet unique and ubiquitous B2B segment of customized goods. The company focuses on packaging, textiles, apparel, and other contract manufacturing goods as its product portfolio and has a network of over 1500 curated manufacturers across these categories. Bizongo was founded in 2015 by three IIT graduates Aniket Deb, Sachin Agrawal, and Ankit Tomar.
LEAP INDIA is a supply chain solutions company. It offers transportation and storage management, inventory management, and SAP IT solutions to companies.
Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech investigating novel therapeutics for CLDN1+ cancers. Alentis is the pioneering business in the use of anti-CLDN1 ADCs and antibodies to modify and reverse the progression of certain diseases.
Tessian’s mission is to secure the human layer. Using machine learning technology, Tessian automatically stops data breaches and security threats caused by human error - like data exfiltration, accidental data loss, business email compromise, and phishing attacks - with minimal disruption to employees' workflow. As a result, employees are empowered to do their best work, without security getting in their way. Founded in 2013, Tessian is backed by renowned investors like Sequoia, Accel, March Capital, and Balderton, and has offices in San Francisco and London.
HAYA Therapeutics is a developer of RNA-based therapeutics created to treat heart failure. The company's therapeutics utilizes biopharmaceutical therapy to target a heart specific regulator of fibrosis, the long noncoding RNA, enabling physicians to to block myocardial fibrosis and treat heart failure.
Bizongo develops a tech-enabled B2B e-commerce and supply chain platform for packaging, apparel, and other customized goods. It digitally transforms the fragmented and unorganized yet unique and ubiquitous B2B segment of customized goods. The company focuses on packaging, textiles, apparel, and other contract manufacturing goods as its product portfolio and has a network of over 1500 curated manufacturers across these categories. Bizongo was founded in 2015 by three IIT graduates Aniket Deb, Sachin Agrawal, and Ankit Tomar.
Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders. The company also develops breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of the natural functioning of the brain. The inhibitors act with a new mechanism of action that enables restoration of the natural function of the brain by rebalancing altered neurotransmission in different areas of the bran. There is a high demand for new pharmacological treatments in this area especially for certain diseases such as post-traumatic stress disorder (PTSD) which has a high unmet medical need.
Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB platform creates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery. MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
Araris Biotech AG (Araris) is a biotechnology start-up company. Their aim is to deliver a breakthrough technology platform that enables the development of next-generation ADC-based safe and potent drugs for various diseases and ailments.They are committed to produce high quality ADCs that do not require any engineering (antibody and/or cell-line) for site-specific conjugation instead the antibodies can directly be taken 'off-the-shelf'. The site-specifically modified ADCs can thus be produced rapidly within a few days and quality control and analysis can be performed quickly with high confidence. Their ADC technology is backed by two patents.
Cedilla is a developer of therapeutics technologies intended to broaden the reach of small molecule therapeutics. The company's technology is focused on destabilizing oncoprotein targets that are also applicable to therapies outside of oncology, enabling doctors to treat diseases caused by protein dysregulation. The company was founded in 2018 and based in Cambridge, Massachusetts.
Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomal storage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs.
iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. The company aims to improve current immune checkpoint therapies by developing novel drugs with potential safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology.
MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.
Goldfinch is a clinical-stage biotech company focused on discovering and developing precision therapies for patients with kidney disease. It is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates to treat patients with kidney disease. Its Product Engine will industrialize the integration of genetics and kidney biology and confer a differentiated ability to identify, validate, and pursue novel therapeutic targets to treat progressive kidney disease. The company was founded in 2016 and is based in Cambridge, Massachusetts.
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that it is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting two Phase 2a trials of PLN-74809 for the treatment of IPF and plans to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.
Bizongo develops a tech-enabled B2B e-commerce and supply chain platform for packaging, apparel, and other customized goods. It digitally transforms the fragmented and unorganized yet unique and ubiquitous B2B segment of customized goods. The company focuses on packaging, textiles, apparel, and other contract manufacturing goods as its product portfolio and has a network of over 1500 curated manufacturers across these categories. Bizongo was founded in 2015 by three IIT graduates Aniket Deb, Sachin Agrawal, and Ankit Tomar.
iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. The company aims to improve current immune checkpoint therapies by developing novel drugs with potential safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology.
ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
Araris Biotech AG (Araris) is a biotechnology start-up company. Their aim is to deliver a breakthrough technology platform that enables the development of next-generation ADC-based safe and potent drugs for various diseases and ailments.They are committed to produce high quality ADCs that do not require any engineering (antibody and/or cell-line) for site-specific conjugation instead the antibodies can directly be taken 'off-the-shelf'. The site-specifically modified ADCs can thus be produced rapidly within a few days and quality control and analysis can be performed quickly with high confidence. Their ADC technology is backed by two patents.
Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines. REVOLUTION Medicines builds upon the vision of the company’s founder, Martin D. Burke, M.D., Ph.D., professor of chemistry, University of Illinois at Urbana-Champaign, and Early Career Scientist of the Howard Hughes Medical Institute, who invented a transformative method for synthesizing original compounds that are pharmaceutically optimized analogues of complex natural products. REVOLUTION Medicines has entered into an exclusive license agreement with the University of Illinois to practice and expand this technology. REVOLUTION Medicines’ approach is a rapid, standardized and powerful process for assembling simple “chemical building blocks” into refined natural product-like structures. These optimized compounds have significant potential as best-in-class drug candidates.
Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech investigating novel therapeutics for CLDN1+ cancers. Alentis is the pioneering business in the use of anti-CLDN1 ADCs and antibodies to modify and reverse the progression of certain diseases.
ECheng (e成) is a B2B SaaS platform that provides HR matching and resume screening for enterprises. Using machine learning, data mining, and NLP (natural language processing), the company categorizes resumes that best fit the job requirements of the client company. The company was launched in 2013 by industry veterans from Baidu, IBM, and Microsoft, serving multinational conglomerates as well as small and medium-sized companies.
Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology.
ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that it is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting two Phase 2a trials of PLN-74809 for the treatment of IPF and plans to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.
Decibel Therapeutics is a developer of hearing disorder therapeutics intended to protect, repair and restore hearing. The company's therapeutics have provided insights into the link between hearing dysfunction and inner ear pathology and it has capabilities to encompass animal models, drug delivery to the inner ear, imaging, inner ear PK/PD modeling and measurement, bioinformatics, genetics and target identification, enabling patients to experience hearing loss therapies with different forms of hearing disorders for their recovery.
Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB platform creates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery. MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines. REVOLUTION Medicines builds upon the vision of the company’s founder, Martin D. Burke, M.D., Ph.D., professor of chemistry, University of Illinois at Urbana-Champaign, and Early Career Scientist of the Howard Hughes Medical Institute, who invented a transformative method for synthesizing original compounds that are pharmaceutically optimized analogues of complex natural products. REVOLUTION Medicines has entered into an exclusive license agreement with the University of Illinois to practice and expand this technology. REVOLUTION Medicines’ approach is a rapid, standardized and powerful process for assembling simple “chemical building blocks” into refined natural product-like structures. These optimized compounds have significant potential as best-in-class drug candidates.
Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology.
Rethink Robotics helps manufacturers meet the challenges of an agile economy with an integrated workforce, combining trainable, safe and cost-effective robots with skilled labor. Its Baxter robot, driven by Intera, an advanced software platform, gives world-class manufacturers and distributors in automotive, plastics, consumer goods, electronics and more, a workforce multiplier that optimizes labor. With Rethink Robotics, manufacturers increase flexibility, lower costs and can invest in skilled labor—all advantages in fueling continuous innovation and sustainable competitive advantage. Committed to accelerating robotics innovation in manufacturing and beyond, Rethink Robotics’ Baxter Research Robot gives academic and corporate research environments a humanoid robot platform with integrated sensors and an open software development kit for creating custom applications. Based in Boston, Massachusetts, the company is funded by Bezos Expeditions, Charles River Ventures, Highland Capital Partners, Sigma Partners, Draper Fisher Jurvetson, and Two Sigma Ventures.
Aevi’s mission is to build a more open world, where anyone, anywhere, can take or make any kind of payment. Open. Device-agnostic. Solution-independent. Aevi’s cloud-based platform lets payments and transaction data flow across all channels and consumer touchpoints. As the in-person payments expert, Aevi connects digital and in-person channels, orchestrates checkout flows, and sets transaction data free. Today, the award-winning FinTech Aevi operates across Europe, Australia and the US with offices in London, Prague and Paderborn. Setting payments free. | aevi.com | AEVI operates across Europe, Australia and the Americas with offices in London, Prague and Paderborn.
FirstCry is an online portal for baby products and toys. They have over 20000+ items from 250+ top International and Indian brands like Mattel, Ben10, Pigeon, Funskool, Hotwheels, Nuby, Farlin, Medela, Pampers, Disney, Barbie, Gerber, Zapak, Mee Mee, and so on. The company provides best of the products and brands at the best prices with quality online shopping experience, fast and reliable delivery service, and a prompt customer care. FirstCry was founded in 2010 and is based in Pune, India.
Lenskart, the first of its kind online optical store in India, has made it possible to acquire a good quality pair of specs with prescription lenses for just Rs. 399. With a 48-hour free home delivery guarantee and 365 days return policy, Lenskart.com is doing what e-commerce hasn’t been able to do in India yet. The website has over 500 designs of eye frames, in multiple colors, for all age groups, from Rs. 399 all the way to Rs. 4,000 for a pair. All one needs to do is select a frame, fill in their power, and place an order. You can pay online or at the time of delivery. Lenskart.com has the biggest collection of discounted contact lenses consisting of all top-notch brands (viz. Johnson & Johnson, Bausch & Lomb, Ciba Vision to name a few) and be it disposable, toric, colored, or bifocal contact lenses, you can find all possible types here. Lenskart is dedicated to providing its customers with a simple, hassle-free way to replace their contact lenses. One can receive the exact same contact lens, their doctor prescribed, delivered to their door, at a great price.
Private Equity Round in 2014
Airborne International is engaged in engineering, manufacturing, and supplying high-end composites structures for industries such as aerospace, defense, marine, high-end bicycles, and formula-one cars. It offers composites structures maintenance and repair services, including inspection and damage assessment, sealing and painting, and balancing. The company was founded in 1995 and is based in The Hague, the Netherlands.
Private Equity Round in 2013
Secured Mail was established as a licensed postal operator in 2006 by managing director Mark Bigley. It has quickly grown to be the number three player in the wholesale Downstream Access (DSA) marketplace. With DSA, Secured Mail accesses Royal Mail’s Mail Centre network nationwide by collecting customers’ mail direct from the production facility before transporting it back to their own hubs. It is then sorted into mail centre order and delivered nationwide using their own fleet of vehicles. Royal Mail is contracted by Secured Mail to deliver this mail through the letterbox the day after receipt: ‘the Final Mile’. Today, Secured Mail’s client base includes Amazon, Domino’s Pizza and British Gas owner Centrica.